Vimarsana
Biggest News Aggregation in the World

Plus Assay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plus Assay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plus Assay Today - Breaking & Trending Today

Applied BioCode Appoints Industry Veteran Beth Laderman as Chief Scientific Officer - Vimarsana News

Applied BioCode Appoints Industry Veteran Beth Laderman as Chief Scientific Officer

Applied BioCode announced today that Beth Laderman has been appointed as their new Chief Scientific Officer signaling a significant step in the company’s expansion. With 25 years of experience in...

Applied BioCode Announces Distribution Agreement with Medline Industries - Vimarsana News

Applied BioCode Announces Distribution Agreement with Medline Industries

Further Broadens Reach of BioCode® MDx-3000 System into Hospitals and Reference Laboratories in the United States U.S. Distribution of the Automated High Throughput Multiplex Molecular... | May 8, 2023

Applied BioCode, Hardy Diagnostics Ink US Distribution Agreement for MDx System, Test Menu - Vimarsana News

Applied BioCode, Hardy Diagnostics Ink US Distribution Agreement for MDx System, Test Menu

Hardy Diagnostics will begin offering Applied BioCode's MDx-3000 molecular diagnostic system, tests, and analyte specific reagents to US hospitals and reference laboratories.

Source: 360dx.com
DiaSorin S p A : , in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology - Vimarsana News

DiaSorin S p A : , in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology

Message : Required fields DIASORIN, IN PARTNERSHIP WITH QIAGEN, LAUNCHES THE NEW LIAISON® LYMEDETECT® ASSAY BASED ON QUANTIFERON TECHNOLOGY IN COUNTRIES ACCEPTING CE MARK FOR EARLY DIAGNOSIS OF LYME BORRELIOSIS THE LIAISON® LYMEDETECT® ASSAY IS A SOLUTION FOR THE EARLY DIAGNOSIS OF LYME BORRELIOSIS COMBINING DETECTION OF IGG AND IGM ANTIBODIES AND CELLULAR IMMUNITY THE TEST IS AVAILABLE IN COUNTRIES ACCEPTING THE CE MARK AND IS DESIGNED TO BE RUN ON THE LIAISON® XL AND LIAISON® XS PLATFORMS IN CLINICAL STUDIES, THE ASSAY SHOWED, WITHIN 21 DAYS FROM ...